Literature DB >> 20130418

The incidence of myasthenia gravis: a systematic literature review.

Anita McGrogan1, Samantha Sneddon, Corinne S de Vries.   

Abstract

BACKGROUND: A systematic review of literature published between 1980 and 2007, on the incidence of myasthenia gravis, was undertaken.
METHODS: All relevant papers found through searches of Medline, Embase and Science Direct were critically appraised and an assessment was made of the reliability of the reported incidence data.
RESULTS: Thirty-one studies were included in the review, the majority of which investigated populations in Europe. The incidence rates reported were between 3.0 and 30.0/1,000,000/year. However, it is thought that the rates at the upper end of this range, reported by the prospective studies, provided the most accurate estimates. Overall, incidence rates have increased over time owing to a greater awareness of the disease and improved methods of diagnosis.
CONCLUSIONS: The most accurate estimate of incidence of myasthenia gravis was around 30/ 1,000,000/year. The incidence in children and adolescents aged 0-19 years was found to be between 1.0 and 5.0/ 1,000,000/year. The rates presented in this review are likely to be an underestimate of the true incidence rates, as mild cases will have been missed and cases in the elderly will have been misdiagnosed. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20130418     DOI: 10.1159/000279334

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  47 in total

Review 1.  Treatment of myasthenia gravis.

Authors:  Vikas Kumar; Henry J Kaminski
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

3.  Incidence of autoimmune diseases in patients with scabies: a nationwide population-based study in Taiwan.

Authors:  Jui-Ming Liu; Feng-Hsiang Chiu; Chien-Yu Lin; Fung-Wei Chang; Ren-Jun Hsu
Journal:  Rheumatol Int       Date:  2017-04-18       Impact factor: 2.631

4.  Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.

Authors:  Qian-Sheng Yu; Harold W Holloway; Weiming Luo; Debomoy K Lahiri; Arnold Brossi; Nigel H Greig
Journal:  Bioorg Med Chem       Date:  2010-05-12       Impact factor: 3.641

5.  Myasthenia gravis: a changing pattern of incidence.

Authors:  I Casetta; E Groppo; R De Gennaro; E Cesnik; L Piccolo; S Volpato; E Granieri
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

6.  Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.

Authors:  Chad Heatwole; Nicholas Johnson; Robert Holloway; Katia Noyes
Journal:  J Clin Neuromuscul Dis       Date:  2011-12

7.  Candida esophagitis as the cause of swallowing disturbances in an 85-year-old patient with myasthenia gravis.

Authors:  S Ebert; K-P Schweiger; R Nau
Journal:  Z Gerontol Geriatr       Date:  2011-08       Impact factor: 1.281

8.  Estimation of incidence, prevalence, and age-at-diagnosis of myasthenia gravis among adults by hospital discharge records.

Authors:  Anett Foldvari; Nora Kovacs; Valeria Sipos; Gabriella Merth; Ferenc Vincze; Maria Szucs; Janos Sandor
Journal:  Wien Klin Wochenschr       Date:  2015-05-20       Impact factor: 1.704

Review 9.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

10.  The co-existence of myasthenia gravis in patients with myositis: a case series.

Authors:  Julie J Paik; Andrea M Corse; Andrew L Mammen
Journal:  Semin Arthritis Rheum       Date:  2013-12-18       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.